Is Protalix BioTherapeutics Inc. (PLX) A Good Investment?


Protalix BioTherapeutics Inc. (AMEX:PLX) traded with an addition of $0.03 to close at $1.24 on Thursday, an upside of 2.80 percent. An average of 417,542 shares of common stock have been traded in the last five days. There was a fall of -$0.0450 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 374,275 shares traded, while the 50-day average volume stands at 224,762.

PLX stock has increased by 9.01% in the last month. The company shares reached their 1-month lowest point of $1.0700 on 11/30/22. With the stock rallying to its 52-week high on 04/04/22, shares of the company touched a low of $0.70 and a high of $2.00 in 52 weeks. It has reached a new high 7 times so far this year and achieved 45.49% or $0.4033 in price. In spite of this, the price is down -37.81% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Financial Health

Its gross profit as reported stood at $22.0 million compared to revenue of $38.35 million.

Earnings Surprise

In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$3.57 million in the quarter, while revenues of -$5.33 million were shrunk -17.65%. The analyst consensus anticipated Protalix BioTherapeutics Inc.’s latest quarter earnings to come in at -$0.15 per share, but it turned out to be -$0.07, a 53.30% surprise. For the quarter, EBITDA amounted to -$2.77 million. Shareholders own equity worth $50.67 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Protalix BioTherapeutics Inc. (PLX) price momentum. RSI 9-day as of the close on 28 December was 60.83%, suggesting the stock is Neutral, with historical volatility in this time frame at 68.78%.

As of today, PLX’s price is $1.2010 -3.52% or -$0.0450 from its 5-day moving average. PLX is currently trading +12.27% higher than its 20-day SMA and +11.26% higher than its 100-day SMA. However, the stock’s current price level is +18.75% above the SMA50 and +41.95% above the SMA200.

The stochastic %K and %D were 40.48% and 33.07%, respectively, and the average true range (ATR) was 0.0581. With the 14-day stochastic at 50.00% and the average true range at 0.0561, the RSI (14) stands at 60.46%. The stock has reached 0.0012 on the 9-day MACD Oscillator while the 14-day reading was at 0.0233.

Analyst Ratings

H.C. Wainwright reiterated its a Buy rating on Protalix BioTherapeutics Inc. (AMEX: PLX), but raised their price target to $3, indicating a potential price increase of 58.67% for the stock. The consensus rating for Protalix BioTherapeutics Inc. (PLX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PLX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is PLX’s price target for the next 12 months?

Analysts predict a range of price targets between $11.00 and $11.00, with a median target of $11.00. Taking a look at these predictions, the average price target given by analysts for Protalix BioTherapeutics Inc. (PLX) stock is $11.00.


Please enter your comment!
Please enter your name here